EXTON, Pa., Feb. 2, 2018 /PRNewswire/ — The most recent quarterly update of RealTime Dynamix™: Atopic Dermatitis based on 102 dermatologists surveyed in mid-January reveals that use of both Pfizer’s Eucrisa and Sanofi-Regeneron’s Dupixent may be reaching a plateau moving into 2018….
